BG
MYOV

Bellevue Group’s Myovant Sciences Ltd. MYOV Stock Holding History

Bellevue Group’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,910,639
Closed -$159M – 177
2022
Q4 		$159M Sell
5,910,639
-2,000
-0% -$52.6K 2.11% 12
2022
Q3 		$106M Sell
5,912,639
-7,000
-0.1% -$112K 1.52% 17
2022
Q2 		$73.6M Buy
5,919,639
+60,600
+1% +$669K 1.04% 30
2022
Q1 		$78M Sell
5,859,039
-310,000
-5% -$4.16M 0.91% 39
2021
Q4 		$96.1M Buy
6,169,039
+400,000
+7% +$7.64M 0.99% 34
2021
Q3 		$129M Buy
5,769,039
+500,000
+9% +$11M 1.31% 21
2021
Q2 		$120M Buy
5,269,039
+75,000
+1% +$1.58M 1.17% 23
2021
Q1 		$107M Buy
5,194,039
+390,000
+8% +$8.88M 1.13% 30
2020
Q4 		$133M Sell
4,804,039
-287,961
-6% -$5.61M 1.52% 21
2020
Q3 		$71.5M Buy
5,092,000
+445,000
+10% +$8.28M 0.99% 30
2020
Q2 		$95.8M Sell
4,647,000
-168,109
-3% -$2.29M 1.36% 16
2020
Q1 		$36.4M Hold
4,815,109
– – 0.71% 39
2019
Q4 		$74.7M Hold
4,815,109
– – 1.18% 25
2019
Q3 		$25M Buy
4,815,109
+905,000
+23% +$6.71M 0.47% 51
2019
Q2 		$35.4M Buy
+3,910,109
New +$58.3M 0.6% 42

Other funds holding MYOV

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bellevue Group's MYOV Position: Q1 2023 in Review

Bellevue Group sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 5,910,639 shares — an estimated $159M sold.

Bellevue Group first reported a position in MYOV in Q2 2019 and held it in 15 quarters. The position peaked at $159M in Q4 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

  • Bellevue Group reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
  • Bellevue Group sold 5,910,639 Myovant Sciences Ltd. shares in Q1 2023, an estimated $159M.
  • Bellevue Group first reported a position in Myovant Sciences Ltd. in Q2 2019 and held it in 15 quarters.
  • Bellevue Group's Myovant Sciences Ltd. position peaked at $159M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.